Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine

被引：4
作者：
Tomova, A.
Brodowicz, T.
Tzekova, V.
Timcheva, C.
Wiltschke, C.
Gerges, D. A.
Pawlega, J.
Spanik, S.
Inbar, M. J.
Zielinski, C. C.
机构：
[1] Plovdiv Canc Ctr, Plovdiv, Bulgaria
[2] Univ Vienna, Dept Med 1, Vienna, Austria
[3] Univ Hosp, Sofia, Bulgaria
[4] SBALO Natl Oncol Ctr, Sofia, Bulgaria
[5] Rizk Hosp, Beirut, Lebanon
[6] Klin Onkol CmuJ, Krakow, Poland
[7] Onkol Ustav Sv Alzbety, Bratislava, Slovakia
[8] Sourasky Med Ctr, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.1106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1106
引用
收藏
页数：1
相关论文
共 50 条
[21]   Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma [J].
Liu, Zhiyong ;
Wang, Xin ;
Wang, Jiaqiang ;
Zhang, Peng ;
Li, Chao ;
Wang, Bangmin ;
Liu, Guancong ;
Yao, Weitao .
FRONTIERS IN ONCOLOGY, 2022, 12
[22]   Docetaxel/gemcitabine/toripalimabVarious toxicities [J].
Reactions Weekly, 2024, 1995 (1) :73-73
[23]   Docetaxel/gemcitabine/nivolumabLack of efficacy [J].
Reactions Weekly, 2024, 2014 (1) :240-240
[24]   A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer [J].
Artz, A ;
Stadler, WM ;
Vogelzang, NJ ;
Zimmerman, T ;
Ryan, C .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (02) :109-113
[25]   Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer [J].
Seidman, A. D. ;
Brufsky, A. ;
Ansari, R. H. ;
Hart, L. L. ;
Stein, R. S. ;
Schwartzberg, L. S. ;
Stewart, J. F. ;
Russell, C. A. ;
Chen, S. -C. ;
Fein, L. E. ;
Vargas, J. A. De La Cruz ;
Kim, S. -B. ;
Cavalheiro, J. ;
Zhao, L. ;
Gill, J. F. ;
Obasaju, C. K. ;
Orlando, M. ;
Tai, D. F. .
ANNALS OF ONCOLOGY, 2011, 22 (05) :1094-1101
[26]   Sequential chemotherapy with gemcitabine plus carboplatin, followed by additional docetaxel for aged patients with advanced upper-tract urothelial cancer. [J].
Yoneyama, Takahiro ;
Tobisawa, Yuki ;
Yoneyama, Tohru ;
Yamamoto, Hayato ;
Imai, Atsushi ;
Mori, Kazuyuki ;
Hatakeyama, Shingo ;
Hashimoto, Yasuhiro ;
Koie, Takuya ;
Ohyama, Chikara .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[27]   A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma [J].
Cho, May ;
Wang-Gillam, Andrea ;
Myerson, Robert ;
Gao, Feng ;
Strasberg, Steven ;
Picus, Joel ;
Sorscher, Steven ;
Fournier, Chloe ;
Nagaraj, Gayathri ;
Parikh, Parag ;
Suresh, Rama ;
Linehan, David ;
Tan, Benjamin R. .
HPB, 2015, 17 (07) :587-593
[28]   Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results [J].
Chan, S. ;
Romieu, G. ;
Huober, J. ;
Tubiana-Hulin, M. ;
Schneeweiss, A. ;
Lluch, A. ;
Llombart, A. ;
du Bois, A. ;
Carrasco, E. ;
Thareau, Vaury A. ;
Fumoleau, P. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 :S68-S68
[29]   Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial [J].
Binder, Daniel ;
Beinert, Thomas ;
Schweisfurth, Hans ;
Grah, Christian ;
Temmestfeld-Wollbrueck, Bettina ;
Schaeper, Christoph ;
Mueller-Hagen, Gerit ;
Schuermann, Dirk ;
Suttorp, Norbert .
ANNALS OF ONCOLOGY, 2004, 15 :178-178
[30]   SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer [J].
P A Vasey ;
R Atkinson ;
R Osborne ;
D Parkin ;
R Symonds ;
J Paul ;
L Lewsley ;
R Coleman ;
N S Reed ;
S Kaye ;
G J S Rustin .
British Journal of Cancer, 2006, 94 :62-68
12345